News
Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...
NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD Sergey N. Avdeev Viliya V. Gaynitdinova Qingyun Ma Research Open Access 01 Jul 2025 Scientific Reports Volume: 15, P: 21169 ...
BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.
Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results